title: Fully activated MEK1 exhibits compromised affinity for binding of allosteric inhibitors U0126 and PD0325901.
abstract: Kinases catalyze the transfer of γ-phosphate from ATP to substrate protein residues triggering signaling pathways responsible for a plethora of cellular events. Isolation and production of homogeneous preparations of kinases in their fully active forms is important for accurate in vitro measurements of activity, stability, and ligand binding properties of these proteins. Previous studies have shown that MEK1 can be produced in its active phosphorylated form by coexpression with RAF1 in insect cells. In this study, using activated MEK1 produced by in vitro activation by RAF1 (pMEK1(in vitro)), we demonstrate that the simultaneous expression of RAF1 for production of activated MEK1 does not result in stoichiometric phosphorylation of MEK1. The pMEK1(in vitro) showed higher specific activity toward ERK2 protein substrate compared to the pMEK1 that was activated via coexpression with RAF1 (pMEK1(in situ)). The two pMEK1 preparations showed quantitative differences in the phosphorylation of T-loop residue serine 222 by Western blotting and mass spectrometry. Finally, pMEK1(in vitro) showed marked differences in the ligand binding properties compared to pMEK1(in situ). Contrary to previous findings, pMEK1(in vitro) bound allosteric inhibitors U0126 and PD0325901 with a significantly lower affinity than pMEK1(in situ) as well as its unphosphorylated counterpart (npMEK1) as demonstrated by thermal-shift, AS-MS, and calorimetric studies. The differences in inhibitor binding affinity provide direct evidence that unphosphorylated and RAF1-phosphorylated MEK1 form distinct inhibitor sites.
authors.affiliation: Protein Science Department, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA. payal.sheth@merck.com
authors.forename: Payal R
authors.initials: PR
authors.lastname: Sheth
authors.forename: Yuqi
authors.initials: Y
authors.lastname: Liu
authors.forename: Thomas
authors.initials: T
authors.lastname: Hesson
authors.forename: Jia
authors.initials: J
authors.lastname: Zhao
authors.forename: Lev
authors.initials: L
authors.lastname: Vilenchik
authors.forename: Yan-Hui
authors.initials: YH
authors.lastname: Liu
authors.forename: Todd W
authors.initials: TW
authors.lastname: Mayhood
authors.forename: Hung V
authors.initials: HV
authors.lastname: Le
mesh_terms: D000494:Allosteric Regulation / Q000187:drug effects / Q000502:physiology; D000818:Animals; D001549:Benzamides / Q000378:metabolism* / Q000494:pharmacology; D002070:Butadienes / Q000378:metabolism* / Q000494:pharmacology; D002460:Cell Line; D004159:Diphenylamine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects / Q000502:physiology; D007313:Insecta; D019950:Mitogen-Activated Protein Kinase 1 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009570:Nitriles / Q000378:metabolism* / Q000494:pharmacology; D011485:Protein Binding / Q000187:drug effects / Q000502:physiology; D047428:Protein Kinase Inhibitors / Q000378:metabolism / Q000494:pharmacology
chemical_list: D001549:Benzamides; D002070:Butadienes; D009570:Nitriles; D047428:Protein Kinase Inhibitors; C113580:U 0126; C506614:mirdametinib; D004159:Diphenylamine; D019950:Mitogen-Activated Protein Kinase 1